TY - GEN A1 - Adefioye, Olusolabomi J. A1 - Weinreich, Jörg A1 - Rödiger, Stefan A1 - Schierack, Peter A1 - Olowe, Olugbenga Adekunle T1 - Phylogenetic Characterization and Multilocus Sequence Typing of Extended-Spectrum Beta Lactamase-Producing Escherichia coli from Food-Producing Animals, Beef, and Humans in Southwest Nigeria T2 - Microbial Drug Resistance Y1 - 2021 U6 - https://doi.org/10.1089/mdr.2019.0397 SN - 1931-8448 SN - 1076-6294 VL - 27 IS - 1 SP - 111 EP - 120 ER - TY - GEN A1 - Chilimoniuk, Jarosław A1 - Gosiewska, Alicja A1 - Słowik, Jadwiga A1 - Weiss, Romano A1 - Deckert, P. Markus A1 - Rödiger, Stefan A1 - Burdukiewicz, Michał T1 - coutfitteR: efficient selection of count distributions to assess DNA damage T2 - Annals of Translational Medicine Y1 - 2021 U6 - https://doi.org/10.21037/atm-20-6363 SN - 2305-5847 VL - 9 IS - 7 ER - TY - GEN A1 - Hanschmann, Henning A1 - Rödiger, Stefan A1 - Kramer, Toni A1 - Hanschmann, Katrin A1 - Steidle, Michael A1 - Fingerle, Volker A1 - Schmidt, Carsten A1 - Lehmann, Werner A1 - Schierack, Peter T1 - LoopTag FRET Probe System for Multiplex qPCR Detection of Borrelia Species T2 - Life Y1 - 2021 U6 - https://doi.org/10.3390/life11111163 SN - 2075-1729 VL - 11 IS - 11 ER - TY - GEN A1 - Schmidt, Carsten A1 - Borcherding, Heike A1 - Thiele, Thomas A1 - Schedler, Uwe A1 - Werner, Franziska A1 - Rödiger, Stefan A1 - Roggenbuck, Dirk A1 - Schierack, Peter T1 - Fluorescence-encoded poly (methyl metharcylate) nanoparticles for a lateral flow assay detecting IgM autoantibodies in rheumatoid arthritis T2 - Analytical biochemistry Y1 - 2021 U6 - https://doi.org/10.1016/journal.ppat.1010118 SN - 1096-0309 VL - Vol. 633 ER - TY - GEN A1 - Khan, Muhammad Moman A1 - Kolenda, Rafał A1 - Schierack, Peter A1 - Weinreich, Jörg A1 - Rödiger, Stefan A1 - Schierack, Jakob A1 - Stubbe, Michael A1 - Lkhagvasuren, Davaa A1 - Guenther, Sebastian A1 - Schaufler, Katharina T1 - Investigation of Commensal Escherichia coli Populations of Cormorant Hatchlings in the Absence of Anthropogenic Impacts in Remote Areas of West Mongolia T2 - Microorganisms Y1 - 2021 U6 - https://doi.org/10.3390/microorganisms9020372 SN - 2076-2607 VL - 9 IS - 2 ER - TY - GEN A1 - Schmidt, Jonas A1 - Berghaus, Sandro A1 - Blessing, Frithjof A1 - Wenzel, Folker A1 - Herbeck, Holger A1 - Blessing, Josef A1 - Schierack, Peter A1 - Rödiger, Stefan A1 - Roggenbuck, Dirk T1 - A semi-automated, isolation-free, high-throughput SARS-CoV-2 reverse transcriptase (RT) loop-mediated isothermal amplification (LAMP) test T2 - Scientific reports Y1 - 2021 U6 - https://doi.org/10.1038/s41598-021-00827-0 SN - 2045-2322 VL - 11 IS - 1 ER - TY - GEN A1 - Bartlitz, Christin A1 - Kolenda, Rafał A1 - Chilimoniuk, Jarosław A1 - Grzymajlo, Krzysztof A1 - Rödiger, Stefan A1 - Bauerfeind, Rolf A1 - Ali, Aamir A1 - Tchesnokovag, Veronika A1 - Roggenbuck, Dirk A1 - Schierack, Peter T1 - Adhesion of Enteropathogenic, Enterotoxigenic, and Commensal Escherichia coli to the Major Zymogen Granule Membrane Glyoprotein 2 T2 - Applied abd Environmental Microbiology Y1 - 2022 U6 - https://doi.org/10.1128/aem.02279-21 SN - 1098-5536 VL - 88 IS - 5 ER - TY - GEN A1 - Schmidt, Carsten A1 - Kammel, Anne A1 - Tanner, Julian A. A1 - Kinghorn, Andrew B. A1 - Khan, Muhammad Moman A1 - Lehmann, Werner A1 - Menger, Marcus A1 - Schedler, Uwe A1 - Schierack, Peter A1 - Rödiger, Stefan T1 - A Multiparametic Fluorescence Assay for Screening Aptamer-Protein Interactions Based on Microbeads T2 - Scientific Reports Y1 - 2022 U6 - https://doi.org/10.1038/s41598-022-06817-0 SN - 2045-2322 VL - 12 ER - TY - GEN A1 - Fischer, Thomas A1 - Marchetti-Deschmann, Martina A1 - Assis, Ana Cristina A1 - Elad, Michal Levin A1 - Algarra, Manuel A1 - Barac, Marko A1 - Bogdanovic Radovic, Iva A1 - Cicconi, Flavio A1 - Claes, Britt A1 - Frascione, Nunzianda A1 - George, Sony A1 - Guedes, Alexandra A1 - Heaton, Cameron A1 - Heeren, Ron A1 - Lasic, Violeta A1 - Lerma, José Luis A1 - Valle Martinez de Yuso Garcia, Maria del A1 - Nosko, Martin A1 - O'Hara, John A1 - Oshina, Ilze A1 - Palucci, Antonio A1 - Pawlaczyk, Aleksandra A1 - Pospíšková, Kristýna A1 - de Puit, Marcel A1 - Radodic, Ksenija A1 - Rēpele, Māra A1 - Ristova, Mimoza A1 - Romolo, Francesco Saverio A1 - Šafařík, Ivo A1 - Siketic, Zdravko A1 - Spigulis, Janis A1 - Szynkowska-Jozwik, Malgorzata Iwona A1 - Tsiatsiuyeu, Andrei A1 - Vella, Joanna A1 - Dawson, Lorna A1 - Rödiger, Stefan A1 - Francese, Simona T1 - Profiling and imaging of forensic evidence – A pan-European forensic round robin study part 1: Document forgery T2 - Science & Justice Y1 - 2022 U6 - https://doi.org/10.1016/j.scijus.2022.06.001 SN - 1876-4452 SN - 1355-0306 VL - 62 IS - 4 SP - 433 EP - 447 ER - TY - GEN A1 - Lopens, Steffi A1 - Wunsch, Ewa A1 - Milkiewicz, Malgorzata A1 - Röber, Nadja A1 - Zarske, Grit A1 - Nasser, Abdullah A1 - Conrad, Karsten A1 - Laass, Martin W. A1 - Rödiger, Stefan A1 - Krawczyk, Marcin A1 - Roggenbuck, Dirk A1 - Milkiewicz, Piotr T1 - PR3-ANCAs Detected by Third-Generation ELISA Predicts Severe Disease and Poor Survival in Primary Sclerosing Cholangitis T2 - Diagnostics N2 - A highly sensitive detection of anti-neutrophil cytoplasmic antibodies to serine proteinase-3 (PR3-ANCAs) aids in the serological diagnosis of autoimmune liver disorders and the prediction of severity in primary sclerosing cholangitis (PSC). Here, we evaluate a novel third-generation ELISA for the detection of PR3-ANCAs. In total, 309 patients with PSC, 51 with primary biliary cholangitis (PBC), and 120 healthy blood donors (BD) were analyzed. For the survival analysis in PSC, the outcome was defined as liver-transplantation-free survival during the follow-up. Positive PR3-ANCA levels were found in 74/309 (24.0%) of patients with PSC. No BDs and one patient with PBC demonstrated PR3-ANCA positivity. PR3-ANCAs were revealed as independent predictors for a poor PSC outcome (study endpoint: liver transplantation/death, log-rank test, p = 0.02). PR3-ANCA positivity, lower albumin levels, and higher bilirubin concentrations were independent risks of a poor survival (Cox proportional-hazards regression analysis, p < 0.05). The Mayo risk score for PSC was associated with PR3-ANCA positivity (p = 0.01) and the disease severity assessed with a model of end-stage liver disease (MELD) and extended MELD-Na (p < 0.05). PR3-ANCAs detected by a third-generation ELISA are diagnostic and prognostic markers for PSC. Their wider use could help to identify patients who are at-risk of a more severe disease. KW - primary sclerosing cholangitis KW - antibodies against serine protease proteinase-3 KW - survival KW - health-related quality of life KW - liver biochemistry KW - disease severity Y1 - 2022 U6 - https://doi.org/10.3390/diagnostics12112682 SN - 2075-4418 VL - 12 IS - 11 ER - TY - GEN A1 - Azam, Hafiz Muhammad Husnain A1 - Rößling, Rosa Ilse A1 - Geithe, Christiane A1 - Khan, Muhammad Moman A1 - Dinter, Franziska A1 - Hanack, Katja A1 - Prüß, Harald A1 - Husse, Britta A1 - Roggenbuck, Dirk A1 - Schierack, Peter A1 - Rödiger, Stefan T1 - MicroRNA biomarkers as next-generation diagnostic tools for neurodegenerative diseases: a comprehensive review T2 - Frontiers in Molecular Neuroscience N2 - Neurodegenerative diseases (NDs) are characterized by abnormalities within neurons of the brain or spinal cord that gradually lose function, eventually leading to cell death. Upon examination of affected tissue, pathological changes reveal a loss of synapses, misfolded proteins, and activation of immune cells—all indicative of disease progression—before severe clinical symptoms become apparent. Early detection of NDs is crucial for potentially administering targeted medications that may delay disease advancement. Given their complex pathophysiological features and diverse clinical symptoms, there is a pressing need for sensitive and effective diagnostic methods for NDs. Biomarkers such as microRNAs (miRNAs) have been identified as potential tools for detecting these diseases. We explore the pivotal role of miRNAs in the context of NDs, focusing on Alzheimer’s disease, Parkinson’s disease, Multiple sclerosis, Huntington’s disease, and Amyotrophic Lateral Sclerosis. The review delves into the intricate relationship between aging and NDs, highlighting structural and functional alterations in the aging brain and their implications for disease development. It elucidates how miRNAs and RNA-binding proteins are implicated in the pathogenesis of NDs and underscores the importance of investigating their expression and function in aging. Significantly, miRNAs exert substantial influence on post-translational modifications (PTMs), impacting not just the nervous system but a wide array of tissues and cell types as well. Specific miRNAs have been found to target proteins involved in ubiquitination or de-ubiquitination processes, which play a significant role in regulating protein function and stability. We discuss the link between miRNA, PTM, and NDs. Additionally, the review discusses the significance of miRNAs as biomarkers for early disease detection, offering insights into diagnostic strategies. KW - neurodegenerative diseases KW - microRNA KW - biomarkers KW - nervous system KW - diagnostic tools KW - therapeutic tools KW - protein post-translational modifications KW - limitations Y1 - 2024 U6 - https://doi.org/10.3389/fnmol.2024.1386735 SN - 1662-5099 VL - 17 PB - Frontiers Media S.A. ER - TY - GEN A1 - Chilimoniuk, Jarosław A1 - Erol, Anna A1 - Rödiger, Stefan A1 - Burdukiewicz, Michał T1 - Challenges and opportunities in processing NanoString nCounter data T2 - Computational and Structural Biotechnology Journal Y1 - 2024 U6 - https://doi.org/10.1016/j.csbj.2024.04.061 SN - 2001-0370 VL - 23 SP - 1951 EP - 1958 PB - Elsevier BV ER - TY - GEN A1 - Lopens, Steffi A1 - Schierack, Peter A1 - Krause, Jenny A1 - Piaszczyński, Michał A1 - Król, Robert A1 - Staroń, Robert A1 - Krupa, Łukasz A1 - Gutkowski, Krzysztof A1 - Kruk, Beata A1 - Grąt, Michał A1 - Krawczyk, Marek A1 - Patkowski, Waldemar A1 - Glaser, Fabian A1 - Rödiger, Stefan A1 - Grossmann, Kai A1 - Pająk, Jacek A1 - Milkiewicz, Piotr A1 - Lammert, Frank A1 - Zieniewicz, Krzysztof A1 - Schramm, Christoph A1 - Roggenbuck, Dirk A1 - Krawczyk, Marcin T1 - Antimicrobial glycoprotein 2 (GP2) in gallstones, bile fluid and peribiliary glands of patients with primary sclerosing cholangitis T2 - Clinica Chimica Acta Y1 - 2024 U6 - https://doi.org/10.1016/j.cca.2024.119841 SN - 0009-8981 VL - 562 SP - 1 EP - 8 PB - Elsevier BV ER - TY - GEN A1 - Geithe, Christiane A1 - Zeng, Bo A1 - Schmidt, Carsten A1 - Dinter, Franziska A1 - Roggenbuck, Dirk A1 - Lehmann, Werner A1 - Dame, Gregory A1 - Schierack, Peter A1 - Hanack, Katja A1 - Rödiger, Stefan T1 - A multiplex microchamber diffusion assay for the antibody-based detection of microRNAs on randomly ordered microbeads T2 - Biosensors and Bioelectronics: X Y1 - 2024 U6 - https://doi.org/10.1016/j.biosx.2024.100484 SN - 2590-1370 VL - 18 (2024) SP - 1 EP - 7 PB - Elsevier BV ER - TY - GEN A1 - Rödiger, Stefan A1 - Kögler, Martin A1 - Birkholz, Mario T1 - Open-Source software, fediverse and custom ROMs as tools for a sustainable internet T2 - 2024 Electronics Goes Green 2024+ (EGG) Y1 - 2024 UR - https://ieeexplore.ieee.org/document/10631179 U6 - https://doi.org/10.23919/EGG62010.2024.10631179 SP - 1 EP - 13 PB - IEEE CY - Berlin ER - TY - GEN A1 - Brauckhoff, Tim A1 - Rödiger, Stefan T1 - BiopixR - extended vignette for bioimage analysis package in R Y1 - 2024 U6 - https://doi.org/10.5281/zenodo.12744223 ER - TY - GEN A1 - Liedtke, Victoria A1 - Weiss, Romano A1 - Skifov, Anastasia A1 - Rödiger, Stefan A1 - Schenk, Lysann T1 - Fully automated viability and toxicity screening - areliable all‐in‐one attempt T2 - Cancer Medicine N2 - The CRISPR/Cas9 technology is nowadays a common tool for genome editing to achieve new insights into, for example, diagnostics and therapeutics in cancer and genetic disorders. Cell proliferation and anticancer drug response studies are widely used to evaluate the impact of editing. However, these assays are often time‐consuming, expensive, and reproducibility is an issue. To overcome this, we developed a fast and cheap assay that combines a fully automated multispectral fluorescence microscopy platform with a nuclei staining and open‐source software analysis.Here, we generated different LEDGF/p75 model cell lines to validate the effect on proliferation and chemosensitivity. Therefore, a fast protocol for an optimized all‐in‐one attempt for cytotoxicity screenings and proliferation analysis of adherent cells in a 96‐well plate format was established using differential staining with two fluorescent dyes (Hoechst 33342 and propidium iodide) for live/dead cell discrimination. Subsequently, an automated cell nuclei count and analysis were performed using bioimage informatics.With the new established assay technology, up to 50,000 cells/well can be detected and analyzed in a 96‐well plate, resulting in a fast and accurate verification of viability and proliferation with consistency of 98% compared to manual counting. Our screening revealed that LEDGF depletion using CRISPR/Cas9 showed a diminished proliferation and chemosensitivity independent of cell line origin. Moreover, LEDGF depletion caused a significant increase in 𝛾H2AX foci, indicating a substantial increase in DNA double strand breaks. LEDGF/p75 overexpression enhanced proliferation and chemoresistance underlining the role of LEDGF in DNA damage response.Independent of cancer cell type, LEDGF/p75 is a central player in DNA damage repair and is implicated in chemoresistance. Moreover, our automated fluorescence biosensor technology allowed fast and reliable data acquisition without any fixation or additional washing steps. Additionally, data analysis was implemented using the modular open‐source software that can be adapted as needed. Y1 - 2024 U6 - https://doi.org/10.1002/cam4.7392 SN - 2045-7634 VL - 13 IS - 12 PB - Wiley ER - TY - GEN A1 - Brauckhoff, Tim A1 - Kieffer, Coline A1 - Rödiger, Stefan T1 - Extracting Insights from biological images T2 - Journal of Open Source Software Y1 - 2024 U6 - https://doi.org/10.21105/joss.07074 SN - 2475-9066 VL - 9 IS - 102 ER - TY - GEN A1 - Liedtke, Victoria A1 - Rose, Laura A1 - Hiemann, Rico A1 - Nasser, Abdullah A1 - Rödiger, Stefan A1 - Bonaventura, Alena A1 - Winkler, Laura A1 - Sowa, Mandy A1 - Stöckle, Michael A1 - Schierack, Peter A1 - Junker, Kerstin A1 - Roggenbuck, Dirk T1 - Over-Expression of LEDGF/p75 in HEp-2 Cells Enhances Autoimmune IgG Response in Patients with Benign Prostatic Hyperplasia—A Novel Diagnostic Approach with Therapeutic Consequence? T2 - International Journal of Molecular Sciences N2 - Lens epithelium-derived growth factor splice variant of 75 kDa (LEDGF/p75) is an autoantigen over-expressed in solid tumors and acts as a stress-related transcriptional co-activator. Participation of autoimmune responses in the pathophysiology of benign prostatic hyperplasia (PBH) and a corresponding immunosuppressive therapy by TNFalpha antagonists has been recently suggested. Thus, autoAb testing could aid in the diagnosis of BPH patients profiting from such therapy. We generated CRISPR/Cas9 modified HEp-2 LEDGF knock-out (KO) and HEp-2 LEDGF/p75 over-expressing (OE) cells and examined IgG autoantibody reactivity to LEDGF/p75 in patients with prostate cancer (PCa, n = 89), bladder cancer (BCa, n = 116), benign prostatic hyperplasia (BPH, n = 103), and blood donors (BD, n = 60) by indirect immunofluorescence assay (IFA). Surprisingly, we could not detect elevated binding of autoAbs against LEDGF/p75 in cancer patients, but autoAb reactivity to LEDGF/p75 OE cells in about 50% of patients with BPH was unexpectedly significantly increased. Furthermore, a line immunoassay enabling the detection of 18 different autoAbs revealed a significantly increased occurrence of anti-dsDNA autoAbs in 34% of BPH patients in contrast to tumor patients and BD. This finding was confirmed by anti-mitochondrial (mDNA) autoAb detection with the Crithidia luciliae immunofluorescence test, which also showed a significantly higher prevalence (34%) of anti-mDNA autoAbs in BPH. In summary, our study provided further evidence for the occurrence of autoimmune responses in BPH. Furthermore, LEDGF/p75 over-expression renders HEp-2 cells more autoantigenic and an ideal target for autoAb analysis in BPH with a potential therapy consequence. KW - LEDGF/p75 KW - autoimmunity KW - CRISPR/Cas9 KW - dsDNA KW - mDNA Y1 - 2023 U6 - https://doi.org/10.3390/ijms24076166 SN - 1422-0067 VL - 24 IS - 7 ER - TY - GEN A1 - Roei, Tulchinsky A1 - Boris, Gilburd A1 - Yehuda, Shovman A1 - Milena, Tocut A1 - Eleanor, Zeruya A1 - Ariel, Binyaminov A1 - Tima, Davidson A1 - Büttner, Thomas A1 - Nasser, Abdullah A1 - Michel, Juliane A1 - Rödiger, Stefan A1 - Schierack, Peter A1 - Howard, Amital A1 - Roggenbuck, Dirk A1 - Yehuda, Shoenfeld A1 - Ora, Shovman T1 - CytoBead ANA 2 assay : a novel method for the detection of antinuclear antibodies T2 - Scientific reports N2 - Detection of anti-nuclear autoantibodies (ANA) is based on a two-step algorithm including indirect immunofluorescence (IIF) on HEp2 cells and subsequent reflex/confirmatory testing for specific autoantibodies. Simultaneous cell- and microbead-based autoantibody detection by IIF may be utilized for the evaluation of systemic autoimmune rheumatic diseases (SARDs). In the present study, we assessed the performance of CytoBead ANA 2 in the detection of ANA and ANA-specific autoantibodies, compared to ANA IIF and BioPlex™ 2200. We also tested the ability of CytoBead ANA DFS-70 to identify dense-fine speckled (DFS) pattern associated with anti-DFS70 antibodies in non-SARDs patients. Hundred-twelve routine sera samples were assessed by manual CytoBead ANA 2 for the presence of ANA and specific autoantibodies. In parallel, these samples were analyzed by HEp2 ANA IIF test and a subsequent multiplexed assay BioPlex™ 2200 ANA. Twenty-nine ANA-positive samples obtained from non-SARDs patients and exhibiting DFS pattern by ANA IIF were further tested by CytoBead ANA DFS-70. A substantial agreement was observed between classical ANA IIF and manual CytoBead ANA 2 for the detection of ANA (k = 0.74). Discordant results were mainly associated with the presence of anti-SSA/Ro antibodies detected by CytoBead ANA 2 in ANA IIF negative patients. A good to almost perfect agreement was found between CytoBead ANA 2 and BioPlex™ 2200 for detection of specific antibodies with kappa values ranging from 0.70 to 0.90. Twenty samples (68.9%) obtained from 29 ANA IIF positive without SARDs patients exhibited DFS pattern in CytoBead ANA DFS-70, which confirmed the presence of anti-DFS70 antibodies. The diagnostic performance of manual CytoBead ANA 2 for ANA screening and detection of ANA specific antibodies is comparable to the diagnostic performance of ANA IIF followed by BioPlex™ 2200. This novel one-step assay enables simultaneous ANA screening and confirmation and represents a promising alternative approach to the time-consuming and costly two-tier ANA analysis. KW - Anti-nuclear antibodies KW - Anti-DFS70 antibodies KW - Indirect immunofluorescence KW - Multiplexed assay KW - CytoBead technology Y1 - 2025 U6 - https://doi.org/10.1038/s41598-025-04583-3 SN - 2045-2322 VL - 15 IS - 1 SP - 1 EP - 11 PB - Nature Publishing Group UK CY - London ER - TY - GEN A1 - Azam, Hafiz Muhammad Husnain A1 - Mumtaz, Mehvish A1 - Rödiger, Stefan A1 - Schierack, Peter A1 - Hussain, Nazim A1 - Aisha, Ambreen T1 - MicroRNAs in neurodegenerative diseases : from molecular mechanisms to clinical biomarkers, detection methods and therapeutic strategies—advances and challenges T2 - Neurological sciences N2 - Neurodegenerative diseases (NDDs) pose significant challenges in early detection and treatment due to their complex pathophysiology and heterogeneous clinical presentations. MicroRNAs (miRNAs), small noncoding RNAs that regulate gene expression, have emerged as promising diagnostic biomarkers and therapeutic targets in NDDs. Pathological examination of affected tissues reveals early synaptic dysfunction, protein misfolding, and neuroinflammation occur prior to overt clinical symptoms, highlighting the importance of sensitive diagnostics approaches in prodromal stages. This review summarizes for researchers on the role of miRNAs in NDDs by examining their diagnostic potential in biofluids such as blood and cerebrospinal fluid, and their therapeutic applicability through inhibition or replacement strategies. Literature from peer-reviewed databases was assessed with a focus on recent advances in molecular detection platforms, computational modeling of miRNA–mRNA interactions, and preclinical/clinical investigations. More than 2600 human miRNAs have been identified, collectively regulating over half of mammalian protein-coding genes. Quantitative methodologies, particularly reverse transcription quantitative PCR (RT-qPCR), enable reliable miRNA profiling, facilitating early diagnosis and prognosis of NDDs. Therapeutic strategies, including antagomirs, mimics, sponges and viral or non-viral delivery systems, show promise in modulating disease pathways. However, significant challenges remain, including variability in miRNA extraction and quantification protocols, off-target effects, delivery barriers across the blood brain barrier and limited reproducibility across studies. MiRNAs represent a class of molecular tools with potential to transform diagnostics and therapeutics in NDDs. Future research should prioritize methodological standardization, validation in large multicenter cohorts, and improved computational approaches to elucidate miRNA-mediated regulatory networks in NDDs. Replication studies and translational research are essential harnessing the the full clinical utility of miRNAs in the management of Alzheimer disease, Parkinson disease and other NDDs. KW - MicroRNA KW - Neurodegenerative diseases KW - Alzheimer’s disease KW - Parkinson’s disease KW - Huntington’s disease KW - Amyotrophic lateral sclerosis KW - Diagnostic biomarkers KW - MiRNA-based therapeutics KW - Molecular diagnostics KW - Gene regulation KW - Biofluid biomarkers KW - Delivery technologies KW - Neuroinflammation KW - RT-qPCR KW - NGS KW - Clinical translation Y1 - 2025 U6 - https://doi.org/10.1007/s10072-025-08419-w SN - 1590-3478 PB - Springer CY - Milano ER -